Radiopharmaceutical Design Shifts Focus from Peak Yield to Robustness

Radiopharmaceutical development has long been judged by a single headline number: the radiochemical yield achieved under carefully optimized laboratory conditions. A new position paper, published open access in EJNMMI Radiopharmacy and Chemistry on 6 September 2026 by Xiaojin Song and Chuangyan Zhai, argues that this obsession with peak performance obscures a critical translational bottleneck. Many promising tracer chemistries, the authors contend, fail not because they cannot be made, but because they cannot be made reliably where it matters.

The core problem is fragility. According to the paper, many radiolabeling systems reach high radiochemical yield only within narrow operational windows and show pronounced sensitivity to minor perturbations in process parameters. When a synthesis moves from a researcher’s hands to an automated synthesis module, or from one production site to several, small deviations in temperature, reagent handling, or timing can erode both yield and purity. The authors attribute this intrinsic chemical fragility to kinetic constraints, trace metal interference, and radiolysis at clinically relevant activity levels.

This matters because clinical production operates under rigid constraints that laboratory optimization rarely reproduces. Automated synthesis modules and multi-center manufacturing demand processes that tolerate real-world variability rather than requiring perfect conditions. A tracer that delivers spectacular yields only when every parameter sits at its optimum is, in translational terms, a liability.

The authors’ proposed remedy is a redefinition of the design goal itself. They argue that radiochemical robustness, defined as consistent yield and purity across a multidimensional design space defined by critical process parameters, should be treated as a primary design criterion rather than an afterthought. In this framing, the question is not how well a labeling chemistry performs on its best day, but how consistently it performs across its worst plausible ones.

This robustness-first view aligns with Quality by Design principles, a regulatory framework familiar from broader pharmaceutical manufacturing. The paper specifies how robustness should be evaluated: through tolerance to environmental variability, reproducibility across scales and activity levels, and compatibility with standardized automated platforms. A chemistry that passes these tests can be transferred between production sites and scaled to clinical activity levels without losing quality.

The position paper focuses specifically on the chemical design phase as the primary origin of translational reliability. By acknowledging that clinical translation is multi-faceted, the authors deliberately narrow their argument: reliability is not injected late in development through process fixes, but should be built in at the level of molecular and labeling chemistry choices.

The conclusion frames robustness-driven design as a de-risking strategy intended to reduce translational failure. Importantly, the authors insist this need not come at the cost of quality: the approach works without compromising strict quality thresholds, and it better aligns radiopharmaceutical development with stringent regulatory requirements and current Good Radiopharmacy Practice, the standards governing the preparation of high-quality medicinal products for patient use.

The paper’s most concrete recommendation is procedural rather than technical: radiochemical robustness should be established as a co-equal criterion alongside biological performance during initial probe selection. In practice, that would mean a candidate tracer’s tolerance to process variability carries the same weight in early selection decisions as its binding affinity or biological targeting, a change the authors argue is necessary to ensure long-term translational viability.

As a perspective piece, the article presents an argument about how the field should prioritize its design criteria, supported by the authors’ characterization of why radiolabeling systems fail under clinical constraints. It does not report new experimental data, but its central claim is testable in principle: tracers selected for robustness across their design space should survive the passage from optimized laboratory synthesis to standardized, multi-center automated production more often than those selected for peak yield alone.

Subject of Research: Radiochemical robustness as a design criterion in radiopharmaceutical development

Article Title: From peak performance to practical robustness in radiopharmaceutical design

Article References: Song, X., & Zhai, C. (2026). From peak performance to practical robustness in radiopharmaceutical design. EJNMMI Radiopharmacy and Chemistry. https://doi.org/10.1186/s41181-026-00497-1

Image Credits: AI Generated

DOI: 10.1186/s41181-026-00497-1

Keywords: radiopharmaceuticals, radiochemical yield, automated synthesis, Quality by Design, clinical translation, radiolabeling, radiolysis, Good Radiopharmacy Practice, probe selection, position paper, peak, performance